# UNAIR Inactivated COVID-19 Vaccine

> **NCT05226429** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Dr. Soetomo General Hospital** · enrollment: 495 (estimated)

## Conditions studied

- COVID-19 Pandemic
- Vaccine Reaction

## Interventions

- **BIOLOGICAL:** UNAIR Inactivated COVID-19 Vaccine
- **BIOLOGICAL:** CoronaVac Biofarma COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT05226429
- **Lead sponsor:** Dr. Soetomo General Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-08
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 495 (ESTIMATED)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226429, "UNAIR Inactivated COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05226429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*